News

Proceeds from this financing will be used to continue to advance the clinical development of the company’s EndoBarrier gastrointestinal liner and endobarrier platform of medical devices for the

The price paid for the common stock is equal to the consolidated closing bid price on the Nasdaq global market on the day of pricing, February 13, 2009.

Dr Sheares is former CEO and member of the board of directors of Reliant Pharmaceuticals. Prior to joining Reliant, Dr Sheares was president of the US human health

Mr Borkowski will remain with the company until a successor is named and in place. Mylan has retained the executive recruitment firm Korn/Ferry International to lead the search

Conbriza, an investigational medicine, is in development by Wyeth Pharmaceuticals, a division of Wyeth. The efficacy of Conbriza was studied in two multicenter, double-blind, randomized Phase III clinical

Mr Kelley has over 20 years of senior executive experience including serving as the chairman of the board of directors, president and CEO of McDATA. Prior to joining

Mr Schmeizl will be responsible for developing and leading the North American sales team, including oversight of sales operations, processes and training. Mr Schmeizl brings to Aushon more

Mr LaPorte was recently retired as senior vice president of business development and general counsel from the company. Prior to Invacare, Mr LaPorte was a partner at Calfee,

In his new role, Dr Moerck will lead Valensa’s move into the next generation of high-performance plant-derived dietary supplements and functional food ingredients, which includes Valensa’s ‘direct to